ArticleJPRAS open2023
Long-term scarring outcomes and safety of patients treated with NovoSorb
Article in JPRAS open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Biodegradable Temporising matrix in the reconstruction of complex wounds: A systematic review and meta-analysis.International wound journal · 2024Pooled it
- Two-stage Reconstruction of Acute Extensive Third-degree Burn Using Biodegradable Temporizing Matrix (NovoSorb BTM).Plastic and reconstructive surgery. Global open · 2026Article
- The Role and Efficacy of NovoSorb Biodegradable Temporizing Matrix in Complex Reconstructive Wounds: A Systematic Review.Plastic and reconstructive surgery. Global open · 2026Article
- Vascularization potential of a dermal skin substitute material (Biodegradable Temporizing Matrix) by proangiogenic growth factors and ASC - an in ovo study.Journal of materials science. Materials in medicine · 2025Article
- The Reconstruction of Various Complex Full-Thickness Skin Defects with a Biodegradable Temporising Matrix: A Case Series.European burn journal · 2025Article
- NovoSorb® Biodegradable Temporizing Matrix: a novel approach for treatment of extremity avulsion injuries in children.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2024Article
- Strategic Use of Biodegradable Temporizing Matrix (BTM) in Wound Healing: A Case Series in Asian Patients.Journal of functional biomaterials · 2024Article
- A Comprehensive Review of Evaluating Donor Site Morbidity and Scar Outcomes in Skin Transfer Techniques.Cureus · 2024Review
- NovoSorb® Biodegradable Temporising Matrix (BTM) for reconstruction of paediatric acute ischaemic limb injuries secondary to sepsis: A literature review and case series.Scars, burns & healingArticle
- A case series to evaluate burn therapy practices after application of Biodegradable Temporising Matrix (BTM).Scars, burns & healingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: NovoSorb Methods: This was a postmarket, multicenter, observational cohort study involving evaluation of long-term outcomes in patients treated with BTM. A total of 55 patients (35 from Royal Adelaide Hospital, South Australia, and 20 from Victoria Adult Burns Service, The Alfred, Victoria) who underwent dermal repair with BTM between 2011 and 2017 were screened for inclusion in this study. All patients had BTM implanted for ≥18 months. Results: Fifteen eligible patients with a mean (SD) age of 49.1 (14.3) years completed study assessments. These patients had a total of 39 areas treated with BTM. Using the Patient and Observer Scar Assessment Scale, scar quality was reported to be good by both observers and patients, with a mean (SD) observer score across all lesions of 3.6 (1.2) and mean (SD) overall opinion of 3.8 (1.2) as well as a mean (SD) patient score of 3.5 (1.2) and overall opinion of 5.0 (2.2). No adverse events or adverse device effects were reported or identified. Conclusion: The long-term scar quality is comparable to published studies. BTM is safe in the long term with no additional risks or adverse consequences being identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.